Background And Aim: The study aims to determine the effects of doxorubicin drug-eluting bead transarterial chemoembolization (DEB-TACE) therapies on health-related quality of life (HRQOL) in patients with unresectable hepatocellular carcinoma (HCC).
Methods: This is a single-center, prospective study assessing HRQOL of consecutive patients with unresectable HCC who underwent DEB-TACE. Longitudinal assessment of HRQOL scores via Short-Form-36 (SF-36) was performed. Baseline HRQOL scores were evaluated for significant change (P < 0.05) pre-therapy, post-therapy, and at 6- and 12-month follow-up. Analysis of overall survival (OS) from HCC diagnosis and OS from first DEB-TACE was performed. Paired t-tests were used to compare HRQOL domain scores.
Results: One hundred eighteen patients (83 male; median age 60 years) were enrolled. Patients had lower baseline scores within all eight HRQOL domains of the SF-36 compared with US age-adjusted healthy norms. No significant changes in all eight domains were observed post-therapy and at 6- or 12-month follow-up compared with baseline (P > 0.05). No significant differences in all eight domains were observed between patients receiving ≥ 4 versus ≤ 3 DEB-TACE (P > 0.05). Both groups were similar for age at HCC diagnosis, gender, ethnicity, HCC etiology, Child-Pugh class and Eastern Cooperative Oncology Group Performance Status (P > 0.05). Patients receiving staged DEB-TACE demonstrated significantly greater median OS from HCC diagnosis (≥ 4 vs ≤ 3 DEB-TACE procedures, 31.9 vs 23.7 months, P = 0.04) and from first DEB-TACE (≥ 4 vs ≤ 3 DEB-TACE, 29.1 vs 20.2 months, P = 0.03).
Conclusion: DEB-TACE therapy for HCC demonstrated long-term preservation of HRQOL. In addition, staged DEB-TACE with four or more therapies does not significantly impact long-term HRQOL compared with patients who received three or fewer therapies.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/jgh.12920 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Background: This case series evaluated the clinical impact and significant technical points of transarterial chemoembolization (TACE) for hepatocellular carcinoma (HCC) using the smaller drug-eluting bead (DEB) M1 (DC Bead M1; 70-150 µm).
Methods: We evaluated 12 patients and 14 HCC nodules treated with DEB-TACE using the DC Bead M1 (named DEM1-TACE). In addition to evaluating the early treatment efficacy for each treated node after DEM1-TACE, the study also used interventional radiology (IVR)- computed tomography (CT) to focus on the presence or absence of retention of the homogeneous contrast medium in target nodules after DEM1-TACE as a predictor of a good treatment response.
Efficacy and safety of transhepatic arterial chemoembolization with drug-loaded microspheres in unresectable primary liver cancer.
World J Gastrointest Oncol
December 2024
State Key Laboratory of Internal Medicine of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing 100700, China.
Background: Transhepatic arterial chemoembolization (TACE), as a local treatment, has been widely used in the treatment of unresectable liver cancer. The introduction of drug carrier microspheres has brought new hope for the therapeutic effect of TACE. Microspheres can realize the slow release and directional delivery of drugs, reduce systemic toxicity and improve local curative effect.
View Article and Find Full Text PDFEfficacy and Safety of Transarterial Chemoembolization Combined with Lenvatinib Plus Programmed Death-1 Inhibitor for Hepatocellular Carcinoma with the Hepatic Vein and/or Inferior Vena Cava Tumor Thrombus.
Cardiovasc Intervent Radiol
December 2024
Department of Interventional Radiology, Fujian Medical University Union Hospital, Fuzhou, 350001, China.
Purpose: The aim of this study was to assess the safety and effectiveness of transarterial chemoembolization (TACE) plus lenvatinib with a programmed death-1 (PD-1) inhibitor compared with TACE plus lenvatinib and TACE alone for hepatocellular carcinoma (HCC) with the hepatic vein and/or inferior vena cava tumor thrombus (HVTT and IVCTT).
Methods: Data on HCC accompanied by HVTT and IVCTT from June 2015 to August 2022 were analyzed in this single-center retrospective study. Drug-eluting bead TACE (DEB-TACE) or conventional TACE (cTACE) was used.
Clinical study of different interventional treatments for primary hepatocellular carcinoma based on propensity-score matching.
World J Gastrointest Surg
November 2024
Department of Oncology, Dangyang People's Hospital, Dangyang 444100, Hubei Province, China.
Article Synopsis
- Transcatheter arterial chemoembolization (TACE) is a key treatment for patients with primary hepatocellular carcinoma (PHC) who cannot have surgery, with two types: conventional TACE (c-TACE) and drug-eluting bead TACE (DEB-TACE), each having different characteristics that affect their effectiveness.
- A study analyzed outcomes of DEB-TACE and c-TACE in PHC patients, using propensity-score matching to ensure balanced comparison, with 86 patients in each group after matching.
- Results showed DEB-TACE had better clinical efficacy, with higher objective response and disease control rates, as well as improved liver function post-treatment, indicating it may be a more effective option for treating PHC
Tumor Suppressor miR-34a: Potential Biomarker of TACE Response in HCC.
Cardiovasc Intervent Radiol
December 2024
Department of Radiology and Nuclear Medicine, University Hospital Brno and Masaryk University Brno, Jihlavská 340/20, 625 00, Brno, Czechia.
Article Synopsis
- The study investigates the effects of TACE treatment on microRNA levels and VEGF in HCC patients, comparing two types of particles: degradable (DSM) and nondegradable (DEB).
- It included 52 patients, measuring biomarker concentrations at different time points before and after TACE to assess treatment responses at six and twelve months.
- Results showed that while both particle types raised microRNA levels post-TACE, only miR-34a’s immediate increase correlated with better outcomes, suggesting it could be a useful biomarker for predicting patient prognosis.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!